Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 16/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979945 | 0.77 | BRD4 (0.45) | ALDH1A1POLBSMN1; SMN2MAPK1 | |
| SCHEMBL6982349 | 0.74 | POLB (0.46) | ALDH1A1POLBSMN1; SMN2MAPK1 | |
| SCHEMBL6978724 | 0.72 | MAPT (0.48) | ALDH1A1POLBPKMADORA2B | |
| SCHEMBL28343399 | 0.71 | ALDH1A1 (0.40) | ALDH1A1POLBSMN1; SMN2PKMADORA2B | |
| SCHEMBL6985757 | 0.70 | MAPT (0.43) | ALDH1A1MCL1 | |
| SCHEMBL6978662 | 0.70 | MAPT (0.43) | ALDH1A1MCL1 | |
| SCHEMBL6981391 | 0.70 | MAPT (0.43) | ALDH1A1MCL1 | |
| SCHEMBL28346706 | 0.67 | PKM (0.39) | ALDH1A1POLBSMN1; SMN2PKMADORA2B | |
| SCHEMBL6988020 | 0.67 | — | — | |
| SCHEMBL28346708 | 0.66 | PKM (0.38) | ALDH1A1POLBSMN1; SMN2PKMADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1145612-C | New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them | — | 2004-04-14 | — | — | CN | disclosed |
| EP-1050530-B1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | SERVIER LAB (FR) | 2003-10-22 | — | — | EP | disclosed |
| US-6451789-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | LES LABORTOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | disclosed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | SULT2A1, GRIN2A, NR3C1 | ALDH1A1 544/4885POLB 2282/4885SMN1; SMN2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.